DEVELOPMENT OF A PROCEDURAL FRAMEWORK FOR INCORPORATION OF ETHICAL CONSIDERATIONS IN HEALTH TECHNOLOGY ASSESSMENT

iii

[1]  Heather Hampel,et al.  Comparing universal Lynch syndrome tumor-screening programs to evaluate associations between implementation strategies and patient follow-through , 2014, Genetics in Medicine.

[2]  E. Dogliotti,et al.  Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. , 2010, European journal of cancer.

[3]  Mita Giacomini,et al.  One of these things is not like the others: the idea of precedence in health technology assessment and coverage decisions. , 2005, The Milbank quarterly.

[4]  M Ryan,et al.  Eliciting public preferences for healthcare: a systematic review of techniques. , 2001, Health technology assessment.

[5]  Kory Jasperson,et al.  Identification of Individuals at Risk for Lynch Syndrome Using Targeted Evaluations and Genetic Testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer Joint Practice Guideline , 2012, Journal of Genetic Counseling.

[6]  R. Goeree,et al.  BARRIERS AND FACILITATORS INFLUENCING ETHICAL EVALUATION IN HEALTH TECHNOLOGY ASSESSMENT , 2015, International Journal of Technology Assessment in Health Care.

[7]  C. Boland,et al.  Who should be sent for genetic testing in hereditary colorectal cancer syndromes? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Lièvre,et al.  Role of microsatellite instability in the management of colorectal cancers. , 2013, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[10]  Angela C. Sodan,et al.  Can computer tools support ethical decision making? , 2004, CSOC.

[11]  A. Goldyne.  Minimizing the influence of unconscious bias in evaluations: a practical guide. , 2007, The journal of the American Academy of Psychiatry and the Law.

[12]  B. Hofmann.  Etikk i vurdering av helsetiltak. Utvikling av en metode for å synliggjøre etiske utfordringer ved vurdering av helsetiltak , 2008 .

[13]  C. Eden,et al.  Strategic management of stakeholders : theory and practice , 2011 .

[14]  Charalabos-Markos Dintsios,et al.  Information on ethical issues in health technology assessment: How and where to find them , 2010, International Journal of Technology Assessment in Health Care.

[15]  H T Lynch,et al.  New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. , 1999, Gastroenterology.

[16]  Christina Niederstadt,et al.  Reporting and presenting information retrieval processes: the need for optimizing common practice in health technology assessment , 2010, International Journal of Technology Assessment in Health Care.

[17]  S. Salloch,et al.  Research across the disciplines: a road map for quality criteria in empirical ethics research , 2014, BMC Medical Ethics.

[18]  D. Hailey,et al.  HTA AGENCIES AND DECISION MAKERS , 2010 .

[19]  Glyn Elwyn,et al.  Process and outcome in communication of genetic information within families: a systematic review , 2007, European Journal of Human Genetics.

[20]  Sudhir Srivastava,et al.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. , 2004, Journal of the National Cancer Institute.

[21]  Finn Børlum Kristensen,et al.  Health Technology Assessment Handbook , 2017 .

[22]  R. Est,et al.  Technology Assessment, Analytic and Democratic Practice , 2012 .

[23]  M. Levine,et al.  Mismatch Repair Deficiency Testing for Patients with Colorectal Cancer: A Clinical and Cost-Effectiveness Evaluation , 2015 .

[24]  R. Goeree,et al.  Evidence-based decision-making 3: Health technology assessment. , 2015, Methods in molecular biology.

[25]  J. Eyles,et al.  Deliberations about deliberative methods: issues in the design and evaluation of public participation processes. , 2003, Social science & medicine.

[26]  C. Deal,et al.  Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decisionmaking framework to growth hormone for Turner syndrome patients , 2010, Cost effectiveness and resource allocation : C/E.

[27]  C. Boland,et al.  Phenotypic and genotypic heterogeneity in the Lynch syndrome: diagnostic, surveillance and management implications , 2006, European Journal of Human Genetics.

[28]  V. Žydžiūnaitė,et al.  Ethical dilemmas concerning decision-making within health care leadership: a systematic literature review. , 2010, Medicina.

[29]  D. Strech.  How factual do we want the facts? Criteria for a critical appraisal of empirical research for use in ethics , 2010, Journal of Medical Ethics.

[30]  D. O'Reilly,et al.  Steps toward improving ethical evaluation in health technology assessment: a proposed framework , 2016, BMC medical ethics.

[31]  Pamela S. Sinicrope,et al.  How do researchers manage genetic results in practice? The experience of the multinational Colon Cancer Family Registry , 2014, Journal of Community Genetics.

[32]  Michelle L Gagnon,et al.  Moving knowledge to action through dissemination and exchange. , 2011, Journal of clinical epidemiology.

[33]  P. Lehoux,et al.  Dissemination of health technology assessments: identifying the visions guiding an evolving policy innovation in Canada. , 2005, Journal of health politics, policy and law.

[34]  Chantale Lessard,et al.  Complexity and reflexivity: two important issues for economic evaluation in health care. , 2007, Social science & medicine.

[35]  M. Synofzik,et al.  Systematic reviews of empirical bioethics , 2008, Journal of Medical Ethics.

[36]  B. Hofmann,et al.  Ethical analysis in HTA of complex health interventions , 2016, BMC Medical Ethics.

[37]  E. Zerbin-Rüdin.  [Genetics in medicine]. , 1969, Wiener medizinische Wochenschrift.

[38]  Bjørn Hofmann,et al.  HARMONIZATION OF ETHICS IN HEALTH TECHNOLOGY ASSESSMENT: A REVISION OF THE SOCRATIC APPROACH , 2014, International Journal of Technology Assessment in Health Care.

[39]  F. Hu,et al.  MLH1 Promoter Methylation Frequency in Colorectal Cancer Patients and Related Clinicopathological and Molecular Features , 2013, PloS one.

[40]  C. Lenk,et al.  Different concepts and models of information for family-relevant genetic findings: comparison and ethical analysis , 2015, Medicine, health care, and philosophy.

[41]  B. Hofmann.  Why ethics should be part of health technology assessment , 2008, International Journal of Technology Assessment in Health Care.

[42]  E. Chiorean.  DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy , 2011 .

[43]  Tom L. Beauchamp,et al.  The ‘Four Principles’ Approach to Health Care Ethics , 2007 .

[44]  J. Coverdale,et al.  Argument-based medical ethics: a formal tool for critically appraising the normative medical ethics literature. , 2004, American journal of obstetrics and gynecology.

[45]  Daniel Strech,et al.  How to write a systematic review of reasons , 2011, Journal of Medical Ethics.

[46]  K. Facey,et al.  Patients' perspectives in health technology assessment: A route to robust evidence and fair deliberation , 2010, International Journal of Technology Assessment in Health Care.

[47]  Michel J. Kaiser,et al.  Ethical Matrix Manual , 2006 .

[48]  A. Grunwald,et al.  The normative basis of (health) technology assessment and the role of ethical expertise , 2004, Poiesis Prax..

[49]  David H. Guston,et al.  Real-time technology assessment , 2020, Emerging Technologies: Ethics, Law and Governance.

[50]  J. Whitty.  An international survey of the public engagement practices of health technology assessment organizations. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[51]  Katrina A B Goddard,et al.  Stakeholder perspectives on implementing a universal lynch syndrome screening program: A qualitative study of early barriers and facilitators , 2015, Genetics in Medicine.

[52]  B. Hofmann.  Why not integrate ethics in HTA: identification and assessment of the reasons , 2014, GMS health technology assessment.

[53]  Dario Sacchini,et al.  INTEGRATING ETHICS IN HEALTH TECHNOLOGY ASSESSMENT: MANY WAYS TO ROME , 2015, International Journal of Technology Assessment in Health Care.

[54]  Mita Giacomini,et al.  Bringing 'the public' into health technology assessment and coverage policy decisions: from principles to practice. , 2007, Health policy.

[55]  Bjørn Hofmann,et al.  Complex health care interventions: Characteristics relevant for ethical analysis in health technology assessment , 2016, GMS health technology assessment.

[56]  Sofia Tranæus,et al.  FRAMEWORK FOR SYSTEMATIC IDENTIFICATION OF ETHICAL ASPECTS OF HEALTHCARE TECHNOLOGIES: THE SBU APPROACH , 2015, International Journal of Technology Assessment in Health Care.

[57]  Ron Goeree,et al.  Methodological guidance documents for evaluation of ethical considerations in health technology assessment: a systematic review , 2014, Expert review of pharmacoeconomics & outcomes research.

[58]  B. Hofmann,et al.  Evaluation of ethical aspects in health technology assessment: more methods than applications? , 2015, Expert review of pharmacoeconomics & outcomes research.

[59]  Bjørn Hofmann,et al.  On value-judgements and ethics in health technology assessment , 2005, Poiesis Prax..